Targets › PRKAG2
1 program from 1 company in 1 trial: 1 Phase 1; Cardiovascular; next expected readout May 2028.
AMP/ATP-binding subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism. In response to reduction of intracellular ATP levels, AMPK activates energy-producing pathways and inhibits energy-consuming processes: inhibits protein, carbohydrate and lipid biosynthesis, as well as cell growth and proliferation. (UniProt, Q9UGJ0)
Open in Phaseline: the race on PRKAG2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Atrium Therapeutics | ATR 1072 siRNA targeting PRKAG2 to reduce gene expression | PRKAG2 | Phase 1 | Cardiac Glycogenosis | May 2028 |
Cardiac Glycogenosis (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.